Skip to main content
Which information about ASPAVELI® are you looking for today?

With increasing clinical investigation and positive phase 3 trial results for complement targeted therapies, Kavanagh et al. proposed a new treatment pathway in 2025.1 

The authors proposed that based on current evidence, Aspaveli® could be positioned as a first-line therapy—alongside background renin–angiotensin–aldosterone system (RAAS) inhibition— for patients presenting with significant proteinuria at diagnosis.1 

Aspaveli - treatment algorithm

Please note that, as of April 2026, Aspaveli® is not included in clinical guidelines for the treatment of C3G or primary IC-MPGN.1,2 

1 pixel spacer
Aspaveli product logo with new endline

EMA indication:

ASPAVELI® is indicated for the treatment of adult and adolescent patients aged 12 to 17 years with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) in combination with a renin-angiotensin system (RAS) inhibitor, unless RAS inhibitor treatment is not tolerated or contraindicated.3

For the full EMA Aspaveli SmPC, please click here

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via their national pharmacovigilance reporting system. Suspected adverse reactions should also be reported to Sobi via email at [email protected].

Abbreviations

ACEi, angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blocker; C3, complement 3; C3G, C3 glomerulopathy; CCB, calcium channel blocker; IC-MPGN, immune complex-mediated membranoproliferative glomerulonephritis; RAAS, renin-angiotensin-aldosterone system; RAASi, RAAS inhibitor.

References

  1. Kavanagh D, et al. Kidney Int Rep. 2026;11(1):17–31. 

  2. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. Kidney Int 2021;100(4S):S1–276.   

  3. Aspaveli Summary of product characteristics. Swedish Orphan Biovitrum AB (publ) January 2026

This website contains information based on the ASPAVELI® Summary of Product Characteristics as approved by European Commission. License conditions vary between countries. Please consult your local Summary of Product Characteristics or Prescribing Information.
 

PP-32965